RARE Daily

March 15, 2023

Rare Daily Staff

Eton Pharmaceuticals, a company focused on developing and commercializing treatments for rare diseases, said it acquired rare disease product candidate ET-600 from Tulex Pharmaceuticals.

ET-600 is an product candidate under development for the treatment of an endocrinology condition that is estimated to impact less than 5,000 pediatric patients in the United States.

“As a rare disease product that builds on our established presence in pediatric endocrinology, ET-600 is a perfect strategic fit for our portfolio,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “We have repeatedly heard from physicians about their need for this product to effectively and safely treat their pediatric patients, so we look forward to working to bring this potential new treatment option to the market.”

Eton expects to submit a New Drug Application for the product to the U.S. Food and Drug Administration in the second quarter of 2024, which could allow for an approval and launch of the product in early 2025. If approved, ET-600 is expected to be a patent-protected, durable product that can generate significant long-term revenue and profit for the company.

Eton currently has three FDA approved products and four late-stage pipeline candidates under development, all of which target endocrine and inherited metabolic conditions.

Photo: Sean Brynjelsen, CEO of Eton Pharmaceuticals

Stay Connected

Sign up for updates straight to your inbox.